Diaceutics PLC (AIM:DXRX) shares moved on the front foot on Thursday after it reported a 20% increase in revenue to £38.5 million for the year ended 31 December.
"2025 marked a step-change year for Diaceutics as we executed an ambitious value-creation programme focused on scale, profitability and recurring revenues," said CEO Ryan Keeling.
Keeling added that the company had accelerated its shift to a high-quality ARR model and entered 2026 with a strong forward pipeline.
The company also returned to profitability and delivered earnings (adjusted EBITDA) growth of approximately 75%, exceeding analyst consensus estimates.
Annual recurring revenue grew 21% to over £20.3 million, while the company’s order book expanded 48% year-on-year to at least £36.8 million. Enterprise-wide engagements increased to ten, generating £13.0 million in ARR across 36 brands. Diaceutics added three new enterprise-wide customers during the period.
Diaceutics expects to achieve 25% revenue growth in 2026.
In London, Diaceutics shares climbed 6% changing hands at 150p.